Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Ovarian Neoplasms 55Small Cell Lung Carcinoma 39Lung Neoplasms 30Carcinoma, Ovarian Epithelial 29Neuroblastoma 25Fallopian Tube Neoplasms 23Uterine Cervical Neoplasms 18Neoplasms 18Leukemia 18Leukemia, Myeloid, Acute 14Precursor Cell Lymphoblastic Leukemia-Lymphoma 13Sarcoma 10Lymphoma 10Brain Neoplasms 9Recurrence 8Carcinoma, Non-Small-Cell Lung 8Unspecified Adult Solid Tumor, Protocol Specific 7Neoplasm Metastasis 7Myelodysplastic Syndromes 7Burkitt Lymphoma 7Blast Crisis 7Neuroectodermal Tumors, Primitive, Peripheral 6Lymphoma, Non-Hodgkin 6Lymphoma, Large B-Cell, Diffuse 6Lymphoma, Follicular 6Leukemia, Myelomonocytic, Chronic 6Leukemia, Myelomonocytic, Acute 6Leukemia, Monocytic, Acute 6Leukemia, Megakaryoblastic, Acute 6Leukemia, Erythroblastic, Acute 6

Interventions

Paclitaxel 16Carboplatin 14Cisplatin 12Oxaliplatin 9Hyperthermic Intraperitoneal Chemotherapy 9Cytoreduction Surgical Procedures 9Fluorouracil 7Bevacizumab 7Doxorubicin 5Leucovorin 4Gemcitabine 4catumaxomab 3Docetaxel 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3nintedanib 2liposomal doxorubicin 2epothilone B 2Surgical Procedures, Operative 2Palliative Care 2Mitomycin 2Laparoscopy 2Interviews as Topic 2Drug Therapy 2Blood Specimen Collection 2veliparib 1tremelimumab 1talimogene laherparepvec 1strattice 1sodium thiosulfate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Peritoneal Neoplasms × Topotecan × Clear all
NCT00317772 2022-02-07

Topotecan and Gefitinib (Iressa) for Ovarian, Peritoneal, or Fallopian Tube Cancer

M.D. Anderson Cancer Center

Phase 1/2 Completed
19 enrolled 12 charts
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms, Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡